Trials / Active Not Recruiting
Active Not RecruitingNCT06544655
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
A Phase 1/1b First-in-human Trial of BMS-986484 as Monotherapy and Combination Therapy in Participants With Advanced Solid Malignancies
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 213 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and tolerability of BMS-986484 administered alone, in combination with nivolumab in participants with advanced/metastatic solid tumors including non-small cell lung cancer (NSCLC), microsatellite stable (MSS) colorectal carcinoma (CRC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), and squamous cell carcinoma of the head and neck (SCCHN).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986484 | Specified dose on specified days |
| BIOLOGICAL | Nivolumab | Specified dose on specified days |
| DRUG | Oxaliplatin | Specified dose on specified days |
| DRUG | Capecitabine | Specified dose on specified days |
| DRUG | Fluorouracil | Specified dose on specified days |
| DRUG | Calcium folinate | Specified dose on specified days |
Timeline
- Start date
- 2024-10-10
- Primary completion
- 2027-10-14
- Completion
- 2027-10-14
- First posted
- 2024-08-09
- Last updated
- 2026-04-17
Locations
9 sites across 3 countries: United States, Australia, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06544655. Inclusion in this directory is not an endorsement.